| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
HX-1171, formerly known as HTHQ, is a lipid peroxidation inhibitor potentially for the treatment of hepatic fibrosis. HTHQ and vitamin E attenuated interleukin-1beta-induced iNOS protein expression in cultured hepatocytes, the potency of HTHQ being 10-times higher than that of vitamin E. HTHQ may prevent tumor production induced by AP and NaNO2 more effectively than ascorbic acid.
| ln Vitro |
Treatment of PC12 cells with HTHQ (0-100 μM; 24 hours) enhances cell viability in a dose-dependent manner [1]. HTHQ (10 μM; 0.6-24 hours; PC12 cells) suppresses p38 mitogen activation Phosphorylation of protein kinase (MAPK), c-Jun N-terminal kinase (JNK1/2), and 3,4-L-dihydroxyphenylalanine (L-DOPA)-induced sustained extracellular signal-regulated kinase (ERK1/2). Additionally, HTHQ promotes cell viability by normalizing Bcl-2-associated X protein (Bax) expression and Bcl-2-associated death protein (Bad) phosphorylation that have been decreased by L-DOPA [1].
|
|---|---|
| ln Vivo |
Serum chemistry levels and liver weights of male Sprague Dawley rats (specific pathogen-free) considerably improved after 4 weeks of oral HTHQ treatment (50-200 mg/kg). Malondialdehyde and hydroxyproline levels in the liver are lowered by HTHQ. Fibrotic septa are also decreased by HTHQ therapy. When HTHQ was administered to mice with DMN-induced liver fibrosis, the amount of mRNA for TGF-β (transforming growth factor-β), α-SMA (α-smooth muscle actin), and PDGF (platelet-derived growth factor) in the liver tissue decreased[2].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: PC12 Cell Tested Concentrations: 0 μM, 1 μM, 10 μM and 100 μM Incubation Duration: 24 hrs (hours) Experimental Results: The significant decrease in cell viability induced by 100 and 200 μM L-DOPA at 24 hrs (hours) was attenuated. Western Blot Analysis[1] Cell Types: PC12 Cell Tested Concentrations: 10 μM Incubation Duration: 0.6-24 hrs (hours) Experimental Results: Inhibition of L-DOPA-induced sustained extracellular signal-regulated kinase (ERK1/2), p38 mitogen-activated protein kinase Phosphorylation (MAPK) and c-Jun N-terminal kinase (JNK1/2). And also normalized the diminished Bcl-2-associated death protein (Bad) phosphorylation and Bcl-2-associated X protein (Bax) expression by L-DOPA. |
| Animal Protocol |
Animal/Disease Models: 48 specific pathogen-free male Sprague Dawley (SD) rats (6 weeks old) were given dimethylnitrosamine (DMN) [2]
Doses: 50 mg/kg, 100 mg/kg, 200 mg /kg Doses: po (po (oral gavage)) lasted for 4 weeks. Experimental Results: Improved DMN-induced liver fibrosis in male SD rats. |
| References |
[1]. Park HJ, et al. 1-O-Hexyl-2,3,5-Trimethylhydroquinone Ameliorates l-DOPA-Induced Cytotoxicity in PC12 Cells. Molecules. 2019 Mar 1;24(5). pii: E867.
[2]. Jung YR et al. Inhibitory Effect of 1-O-Hexyl-2,3,5-Trimethylhydroquinone on Dimethylnitrosamine-induced Liver Fibrosis in Male SD Rats. Toxicol Res. 2010 Sep;26(3):193-201. |
| Molecular Formula |
C15H24O2
|
|---|---|
| Molecular Weight |
236.355
|
| Exact Mass |
236.1776
|
| CAS # |
148081-72-5
|
| Related CAS # |
148081-72-5
|
| SMILES |
OC1=C(C)C=C(OCCCCCC)C(C)=C1C
|
| InChi Key |
ATMNQRRJNBCQJO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H24O2/c1-5-6-7-8-9-17-14-10-11(2)15(16)13(4)12(14)3/h10,16H,5-9H2,1-4H3
|
| Chemical Name |
4-(hexyloxy)-2,3,6-trimethylphenol
|
| Synonyms |
HX-1171 HX-1171 HX-1171 HTHQ
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~423.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (105.78 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 250.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.58 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2308 mL | 21.1542 mL | 42.3083 mL | |
| 5 mM | 0.8462 mL | 4.2308 mL | 8.4617 mL | |
| 10 mM | 0.4231 mL | 2.1154 mL | 4.2308 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA